Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 11/20 | 0.56 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046836 | 0.92 | TAS2R14 (0.53) | CXCR3TAS2R14MEN1KMT2ACA12 | |
| SCHEMBL13399066 | 0.91 | CXCR3 (0.55) | CXCR3TAS2R14MEN1KMT2ACA12 | |
| SCHEMBL5048032 | 0.90 | CXCR3 (0.55) | CXCR3TAS2R14MEN1KMT2ACA12 | |
| SCHEMBL5046908 | 0.88 | CA12 (0.52) | CXCR3TAS2R14MEN1KMT2ACA12 | |
| SCHEMBL13399160 | 0.86 | CXCR3 (0.50) | CXCR3TAS2R14MEN1KMT2ACA12 | |
| SCHEMBL5046407 | 0.86 | TBXAS1 (0.51) | CXCR3TAS2R14MEN1KMT2ACA12 | |
| SCHEMBL5047957 | 0.85 | CXCR3 (0.52) | CXCR3TAS2R14MEN1KMT2ACA12 | |
| SCHEMBL5046357 | 0.85 | CA12 (0.57) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13399054 | 0.84 | TAS2R14 (0.51) | TAS2R14MEN1KMT2ACA12CA1 | |
| SCHEMBL5049429 | 0.84 | PTGER2 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | claimed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | claimed |
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |